Rampart IC Announces the Acquisition of ClearShield
Acquisition combines market leading radiation-attenuating acrylic manufacturer with the market leading interventional suite radiation protection system provider
Birmingham, AL – April 28, 2025 – Rampart IC, the market leader in next generation radiation shielding for interventional suites, today announced the acquisition of ClearShield, a U.S.-based manufacturer of patented, lead-free, radiation-attenuating acrylic. This strategic acquisition fortifies Rampart’s supply chain with a critical material component, further positioning the company at the forefront of safe, sustainable radiation protection for healthcare workers around the world.
ClearShield’s acrylic material delivers exceptional radiation attenuation while offering greater safety, versatility, and environmental compatibility than traditional leaded glass or acrylic materials. Engineered using an acrylic formula infused with bismuth (Bi), a non-toxic and stable element, ClearShield panels are transparent, eco-conscious, and manufactured entirely in the United States. Rampart products incorporate ClearShield acrylic, and together these solutions have been validated as safe and effective through multiple randomized clinical studies and hundreds of successful installations worldwide.
“As the global leader in next generation radiation protection, our customers rely on us for innovation that doesn’t compromise safety or workflow, and this technology directly supports that promise.”
“This acquisition marks a significant strategic milestone for Rampart as we continue to advance the standards of radiation protection,” said Tom Livingston, CEO of Rampart. “ClearShield’s bi-acrylic platform is a perfect fit with our mission to deliver the highest-performing, safest, and most advanced protective solutions available on the market today. As the global leader in next generation radiation protection, our customers rely on us for innovation that doesn’t compromise safety or workflow, and this technology directly supports that promise. In addition, owning the supply chain for the most critical component for all next generation systems enable Rampart to effectively and efficiently meet the growing demand for our products now and in the future.”
“Healthcare teams can have complete confidence in this technology,” said Dr. Bob Foster, founder and CMO of Rampart. “Bismuth acrylic has a proven history of safety and effectiveness in attenuating ionizing radiation in clinical applications. Its versatility allows for seamless customization in imaging environments and supports whole-body protection for everyone in the interventional suite. It’s a major step forward in advancing radiation safety without compromising clinical performance.”
Radiation safety has become a defining issue across the interventional medicine landscape. With an estimated 17 million interventions utilizing radiation performed globally each year, Rampart is uniquely positioned to meet the growing demand for shielding solutions to protect healthcare workers. In addition to healthcare, ClearShield’s applications span a range of high-radiation environments, including nuclear power, government & military use, research laboratories and industrial facilities.
About Rampart IC
Rampart IC is a Birmingham, Alabama-based medical device company whose radiation shielding solutions provide team protection in the interventional suite without the need to wear traditional lead aprons, which can cause orthopedic issues for some team members. Available directly and through distribution partnerships, Rampart’s solutions are implemented in cath labs and other interventional suites worldwide.
About ClearShield
ClearShield manufactures patented, transparent, lead-free, radiation-shielding acrylic in the USA. Using a proprietary bismuth-based compound, ClearShield provides safe, effective X-ray and gamma attenuation for a variety of industries, including healthcare, industrial, nuclear, and defense.